Analysis of the risk factors for allograft vasculopathy in asymptomatic patients after cardiac transplantation.

OBJECTIVE To study the influence of immune and nonimmune risk factors on the development of allograft vasculopathy after cardiac transplantation. METHODS We studied 39 patients with a mean age of 46+/-12 years. The following variables were analyzed: weight (kg), body mass index (kg/m2), donor's age and sex, rejection episodes in the first and second years after transplantation, systolic and diastolic blood pressures (mmHg), total cholesterol and fractions (mg/dL), triglycerides (mg/dL), diabetes, and cytomegalovirus infection. The presence of allograft vasculopathy was established through coronary angiography. RESULTS Allograft vasculopathy was observed in 15 (38%) patients. No statistically significant difference was observed between the two groups in regard to hypertension, cytomegalovirus infection, diabetes, donor's sex and age, rejection episodes in the first and second years after transplantation, and cholesterol levels. We observed a tendency toward higher levels of triglycerides in the group with disease. Univariate and multivariate analyses showed statistically significant differences between the two groups when we analyzed the body mass index (24.53+/-4.3 versus 28.11+/-4.6; p=0.019). CONCLUSION Body mass index was an important marker of allograft vasculopathy in the population studied.

[1]  Rodney X. Sturdivant,et al.  Applied Logistic Regression: Hosmer/Applied Logistic Regression , 2005 .

[2]  R. D. S. Filho.  II Consenso Brasileiro sobre Dislipidemias , 2000 .

[3]  J. Hosenpud,et al.  Coronary artery disease after heart transplantation and its relation to cytomegalovirus. , 1999, American heart journal.

[4]  B. Andersson,et al.  Graft coronary artery disease is strongly related to the aetiology of heart failure and cellular rejections. , 1999, European heart journal.

[5]  I. Castro,et al.  II Consenso Brasileiro Sobre Dislipidemias , 1999 .

[6]  D. Rader,et al.  Lipoprotein(a) levels and heart transplantation atherosclerosis. , 1998, American heart journal.

[7]  F. Harrell,et al.  Relationship of body mass index to subsequent mortality among seriously ill hospitalized patients. SUPPORT Investigators. The Study to Understand Prognoses and Preferences for Outcome and Risks of Treatments. , 1997, Critical care medicine.

[8]  J. Hosenpud,et al.  Cardiac allograft vasculopathy: IgM antibody responses to donor-specific vascular endothelium. , 1997, Transplantation.

[9]  F. Pileggi,et al.  [Lipid profile changes during the late follow-up after heart transplantation]. , 1996, Arquivos brasileiros de cardiologia.

[10]  A. Yeung,et al.  The role of nonimmune risk factors in the development and progression of graft arteriosclerosis: preliminary insights from a multicenter intravascular ultrasound study. Multicenter Intravascular Ultrasound Transplant Study Group. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[12]  R. Wilson,et al.  Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. , 1995, Journal of the American College of Cardiology.

[13]  E. Bocchi,et al.  Incidência de coronariopatia após o transplante cardíaco ortotópico , 1994 .

[14]  S. Hunt,et al.  Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15]  C. R. Smith,et al.  Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  Costanzo-Nordin Mr.  Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  T. Merigan,et al.  A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. , 1992, The New England journal of medicine.

[18]  J. Farmer,et al.  Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. , 1991, The American journal of cardiology.

[19]  M. Hammond,et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.

[20]  L. Stevenson,et al.  Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. , 1990, Circulation.

[21]  V. Starnes,et al.  Eight-year results of cyclosporine-treated patients with cardiac transplants. , 1990, The Journal of thoracic and cardiovascular surgery.

[22]  D. Farge,et al.  [Arterial hypertension in heart transplant recipients]. , 1990, Presse medicale.

[23]  H. Davies,et al.  Coronary arterial pathology in the transplanted human heart. , 1989, International journal of cardiology.

[24]  A. Gotto,et al.  Effects of cyclosporine therapy on plasma lipoprotein levels. , 1989, JAMA.

[25]  V. Starnes,et al.  Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. , 1989, JAMA.

[26]  D. Renlund,et al.  Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression. , 1989, The Journal of heart transplantation.

[27]  Rick S. Blum.  Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. , 1989, The American journal of medicine.

[28]  E. Huang,et al.  Cytomegalovirus infection and viral‐induced transformation of human endothelial cells , 1988, Journal of medical virology.

[29]  L. Simons,et al.  Hyperlipidemia after heart transplantation. , 1988, The Journal of heart transplantation.

[30]  S. Hunt,et al.  Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. , 1987, Circulation.

[31]  P. Reddy,et al.  Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. , 1987, Circulation.

[32]  M. Thompson,et al.  The contrasting effects of cyclosporin-A and azathioprine on arterial blood pressure and renal function following cardiac transplantation. , 1986, International journal of cardiology.

[33]  Mark L. Greenberg,et al.  Long-term hemodynamic follow-up of cardiac transplant patients treated with cyclosporine and prednisone. , 1985, Circulation.

[34]  Manning Feinleib,et al.  Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.

[35]  J. G. Thomson,et al.  Production of severe atheroma in a transplanted human heart. , 1969, Lancet.

[36]  J. Kosek,et al.  Experiences in heart transplantation. Technic, physiology and rejection. , 1968, The American journal of cardiology.

[37]  Sones Fm,et al.  Cine-coronary arteriography. , 1962 .

[38]  A. Haverich,et al.  [Coronary vasculopathy after heart transplantation--effect of temporal onset, severity and progression on long-term prognosis]. , 1999, Zeitschrift fur Kardiologie.

[39]  M. Debakey,et al.  Cytomegalovirus and atherosclerosis. , 1993, European heart journal.

[40]  W. Baumgartner,et al.  Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts. , 1992, The American journal of pathology.

[41]  V. Velebit,et al.  Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. , 1990, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[42]  B. McManus,et al.  Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. , 1990, The Journal of heart transplantation.